Severity
Moderate
FDA Drug recall · Reported November 9, 2016
Failed Stability Specifications: The subject lots exhibited OOS results for Homogeneity test (Moderate separation).
Taro Pharmaceuticals, Inc. recalled Desoximetasone Cream USP, 0.05% 100 g, Rx only, mfd. by Taro Pharmaceuticals Inc. Brampto… - a moderate-severity action.
Desoximetasone Cream USP, 0.05% 100 g, Rx only, mfd. by Taro Pharmaceuticals Inc. Brampto… was recalled by Taro Pharmaceuticals, Inc. in November 9, 2016. Reason: Failed Stability Specifications: The subject lots exhibited OOS results for Homogeneity test (Moderate separa…. Check the official notice for the remedy. Verify recall #D-0117-2017 with the FDA Drug before acting.
The recall
Taro Pharmaceuticals, Inc. issued this moderate-severity FDA Drug recall-Failed Stability Specifications: The subject lots exhibited OOS results for Homogeneity test (Moderate separa….
Sourced from official FDA Drug enforcement records. Verify recall #D-0117-2017 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-0117-2017) was formally reported on November 9, 2016, with the manufacturer initiating the action on September 13, 2016. It is classified under Moderate severity (Class II), with a current status of Terminated. Taro Pharmaceuticals, Inc. is listed as the recalling firm, operating out of Brampton. Federal records list the affected scope as 6,756 units.
The documented reason for this recall is: Failed Stability Specifications: The subject lots exhibited OOS results for Homogeneity test (Moderate separation). Distribution data in the federal record shows the product reached: US & Puerto Rico. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 3 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 1,360 cosmetics & personal care recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified moderate severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Moderate
Affected scope
6,756 units
Related Recalls
6
3 from same agency
Desoximetasone Cream USP, 0.05% 100 g, Rx only, mfd. by Taro Pharmaceuticals Inc. Brampton, Ontario, Canada L6T 1C1, Dist. by: Taro Pharmaceuticals U.S.A., Inc. Hawthorne, NY 10532; NDC 51672-1271-7
Failed Stability Specifications: The subject lots exhibited OOS results for Homogeneity test (Moderate separation).
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Moderate (Class II) |
| Status | Terminated |
| Recall number | D-0117-2017 |
| Date reported | November 9, 2016 |
| Date initiated | September 13, 2016 |
| Recalling firm | Taro Pharmaceuticals, Inc. |
| Firm location | Brampton |
| Affected scope | 6,756 units |
| Distribution | US & Puerto Rico |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
· 2026-06-04
PS Seasoning & Spices, Inc. · 2026-05-27
Fontana Flavors, Inc · 2026-05-27
Wisconsin Pharmacal Company · 2026-05-27
SUN PHARMACEUTICAL INDUSTRIES INC · 2026-04-22
Compare this recall with Tiny Land Children's Play Tents Recalled Due to Risk of Inj… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported November 9, 2016. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.